Ajanta Pharma is a specialty pharmaceutical company based in Mumbai, India, focusing on branded generics across India, Asia, and Africa, with a growing presence in the USA. Established in 1973, it specializes in developing, manufacturing, and marketing finished dosages targeting various therapeutic segments, including cardiology, dermatology, and ophthalmology. The company operates seven state-of-the-art facilities, two of which are US FDA-approved, and has a robust R&D center in Mumbai employing over 750 scientists. Ajanta Pharma has consistently expanded its portfolio, launching 23 new products in FY 2023, including six first-to-market products.
Ajanta's strategy includes a strong chronic-focused product portfolio and a first-to-market approach, allowing it to capitalize on high-growth specialty segments. Its international business spans over 30 emerging countries and includes notable institutional sales, such as anti-malarial supplies under WHO programs. The company actively invests in R&D and infrastructure, with significant capex investments and continuous facility expansions, ensuring its competitive edge in the global pharmaceutical landscape.
